一品红子公司获得丙戊酸钠注射用浓溶液注册证书

Core Viewpoint - The company has received the drug registration certificate for sodium valproate injection solution, allowing it to sell this product in the domestic market, which enhances its competitiveness in chronic disease medications [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration [1] - The approval signifies the company's qualification to market this specific drug in the domestic market, thereby enriching its product pipeline and categories [1] - This development is expected to strengthen the company's competitive position in the chronic disease medication sector [1]